Thomas Ormsby
Associate Professor University of Massachusetts Medical School
Tom Ormsby is a Postdoctoral Associate in Professor Anastasia Khvorova’s lab, focusing on chemically modified oligonucleotide design and extrahepatic siRNA delivery. Previously at Ochre Bio’s Lead Development team working on liver-targeted RNA therapeutics, he brings expertise in RNA therapeutics and bacterial pore-forming toxins.
Seminars
Wednesday 9th December 2026
Enabling Targeted Muscle Delivery Through Aptamer-siRNA Conjugates Beyond Antibody Conjugates
12:00 pm
- Repurposing transferrin receptor 1 (TfR1)-binding aptamers as targeting ligands for systemic siRNA delivery
- Achieves selective and durable siRNA activity in skeletal muscle following a single systemic dose
- Establishes aptamer–siRNA conjugates as a promising platform for next-generation targeted oligonucleotide therapeutics
Wednesday 9th December 2026
Roundtable Discussion: Is Transferrin Receptor Targeting Still the Future of Delivery?
1:30 pm
An interactive panel discussion bringing together experts developing next-generation delivery technologies to debate the future of transferrin receptor targeting, emerging alternatives and the scientific challenges that remain in achieving effective delivery
- Compare the strengths and limitations of IgG, Fab, VHH and bispecific transferrin receptor targeting strategies to understand where each approach is demonstrating the greatest translational potential
- Debate whether continued optimisation of transferrin receptor biology is enough or if the field must identify new receptors and targeting mechanisms to unlock the next generation of oligonucleotide-based therapeutics
- Put your questions directly to the panel and gain practical insights into the opportunities, remaining barriers and future direction of transferrin receptor delivery
